Results 51 to 60 of about 2,368 (193)

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales [PDF]

, 2022
INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease.
Koltai, Mihaly, Flasche, Stefan, Jit, Mark, Atkins, Katherine E; id_orcid, Hodgson, David, Krauer, Fabienne, Atkins, Katherine E   +6 more
core   +1 more source

First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants [PDF]

Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May.
Scarpaleggia M., Rizzo C, Baldo V., Chironna M., Pariani E, Baldo V, Orsi A, Scarpaleggia M, Icardi G, Orsi A., Panatto D, Pariani E., Giuffrida S., Panatto D., Icardi G., Barbone F, Rizzo C., Giuffrida S, Barbone F., Montomoli E., Chironna M, Montomoli E   +20 more
core   +3 more sources

Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract REGN17092, a fully human immunoglobulin (Ig) G1 antibody with M252Y/S254T/T256E (YTE) modification in the Fc portion, was assessed in a first‐in‐human study (ClinicalTrials.gov, NCT05923424). REGN17092 was designed to target the severe acute respiratory coronavirus 2 (SARS‐CoV‐2) S protein.
Maria Rosario, Jan de Hoon, Flonza Isa, Kenneth Turner, Jing Li, Joel Kantrowitz, Samit Ganguly, Sasha Fraser, Zhongqing Will He, Hong Yan, Ana Gonzalez Ortiz, Lori Faria, Ingeborg Heirman, Alina Baum, Thomas D Norton, Yogesh Patel, Veronica Mas Casullo, John D Davis   +17 more
wiley   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

, 2023
International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach, Wählby Hamrén, Ulrika, Mankad, Vaishali, Cabañas, Fernando, Fernando Cabañas, Domachowske, Joseph, Nguyen, Kim A, Kubiak, Robert J, Atanasova, Victoria, Victoria Atanasova, Furuno, Kenji, Robert J Kubiak, Ulrika Wählby Hamrén, Kubiak, Robert, Therese Takas, Leach, Amanda, Banu, Irfana, Nguyen, Kim An, Manish Shroff, Chang, Yue, Kenji Furuno, Kim A Nguyen, Shroff, Manish, Takas, Therese, Joseph B Domachowske, Vaishali S Mankad, Irfana Banu, Tonya Villafana, Yue Chang, Domachowske, Joseph B, Mankad, Vaishali S, Villafana, Tonya   +31 more
core   +1 more source

RSV‐Pre‐F Vaccination During Pregnancy and Neonatal Outcomes—A Systematic Review and Meta‐Analysis

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Objectives Respiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality worldwide. Recent preventive strategies include maternal vaccination and monoclonal antibodies. However, maternal RSV vaccination has raised safety concerns due to possible associations with preterm birth.
Niko Leskinen, Marjut Haapanen, Ilari Kuitunen   +2 more
wiley   +1 more source

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.In this trial ...
Pamela Griffin M., Yuan Y., Takas T., Domachowske J. B., Madhi S. A., Manzoni P., Simoes E. A. F., Esser M. T., Khan A. A., Dubovsky F., Villafana T., DeVincenzo J. P.   +11 more
openaire   +5 more sources

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +1 more source

Estimating the National Disease Burden and Economic Burden of Respiratory Syncytial Virus (RSV) in Thailand

Influenza and Other Respiratory Viruses, Volume 20, Issue 9, September 2026.
ABSTRACT Background Respiratory syncytial virus (RSV), a single‐stranded negative‐sense RNA virus, causes respiratory tract infections in children and adults, leading to hospitalization and mortality. However, the national disease burden and economic impact of RSV in Thailand remain undetermined.
Kansak Boonpattharatthiti, Chonnamet Techasaensiri, Wanatpreeya Phongsamart, Pilailuk Akkapaiboon Okada, Chanthawat Patikorn, Prabda Praphasiri, Teerapon Dhippayom, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +1 more source